Clinical trial
A Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF a Chimeric Monoclonal Antibody (Infliximab, REMICADE) in Pediatric Subjects With Moderate to Severe CROHN'S Disease.
NCT00207675 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF a Chimeric Monoclonal Antibody (Infliximab, REMICADE) in Pediatric Subjects With Moderate to Severe CROHN'S Disease.
- Lead sponsor
- Centocor, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 28, 2003
- Completion date
- August 31, 2007
- Enrollment
- 112 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.